Advancing Brigatinib Properties in anaplastic lymphoma kinase positive non-small cell lung cancer (ALK+ NSCLC) patients by deep phenotyping

Preoperative oxaliplatin-based chemoradiotherapy and consolidation chemotherapy versus fluorouracil-based chemoradiotherapy for MRI-defined intermediate and high-risk rectal cancer patients.

Preoperative FOLFOX versus postoperativ risk-adapted chemotherapy in patients with locally advanced rectal cancer and low risk for local failure: A randomized Phase III Trial of the German Rectal Cancer Study Group.

Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma. A randomized, multidisciplinary AIO/DGAV/DGVS phase III trial.

Adjuvante dynamische, markerangepasste personalisierte Therapie im Vergleich zur endokrinen Therapie plus Ribociclib versus Chemotherapie bei fortgeschrittenem Risiko HR+/ HER2- frühen Brustkrebs (ADAPTcycle)

Prospective randomized trial of an adjuvant therapy of completely resected Merkel Cell Carcinoma (MCC) with immune checkpoint blocking antibodies (Nivolumab, Opdivo; Ipilimumab, Yervoy) versus observation

Postoperative adjuvant radio chemo therapy (aRCH) with Cisplatin (C) versus aRCH with C and Pembrolizumab (P) in locally advanced head and neck squamous cell carcinoma (HNSCC); multicenter randomized Phase II study within the German interdisciplinary study group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk

Atezolizumab in Kombination mit Bevacizumab und Chemotherapie versus Bevacizumab und Chemotherapie beim rezidivierendem Ovarialkarzinom – eine randomisierte Phase III Studie

International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia